With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
There is an increasing epidemic; the threat is real. With prevalence up and recent therapeutic advances few, atrial fibrillation and the accompanying risk for stroke need to be uppermost in the minds of physicians caring for patients with cardiovascular risk factors. Join Dr. Jerry Naccarelli as he leads a panel of experts consisting of Drs. Osseroff, Capucci and Lau, in a discussion of this global problem.
Atrial fibrillation is associated with a high risk for stroke, myocardial infarction, heart failure, and death. How does blockade of the renin-angiotensin system affect patient outcomes? Join our international panel of experts, Drs Camm, Connolly, Crijns, and Granger, as they discuss the ESC 09 hotline results of the ACTIVE-I trial.
Read Dr. Jonathan Piccini's review of prevention of stroke in AF and how the newly released results of clinical trials of novel antithrombotic agents will reduce the risk for stroke. Then listen to our international panel of experts, Drs. Camm, Granger, Prystowsky, and Yusuf, as they give their take on new data released at ESC 2009.
Dr. Ileana Piña discusses the design and outcomes of the MADIT-CRT trial with Drs. Moss and Estes, and how these new data may benefit patients with heart failure.
Evidence-based therapies, both pharmacologic and devices are well documented in published guidelines, but are they followed and implemented in practice? Is there a treatment gap? Is it all about education or the lack thereof? Drs. Yancy, Abraham, and Pfeffer confer on evidence from recent registries and trials.
Join our international panel of experts, Drs. Lip, Halperin, Weitz, Ezekowitz, Wallentin, and Connolly as they present late-breaking results of the RE-LY trial.
AF is sometimes considered a benign or nuisance condition. However, it is vital that it is recognized as a harbinger of underlying cardiovascular disease, and that it is diagnosed early and treated appropriately. Join Drs. Kirchhof, Dorian, Marrouche, and Steg as they discuss strategies to reduce the complications of AF.
Does early intervention with CRT-D slow the progression of heart failure? Watch as Dr. David Cannom interviews Drs. Camm, Hlatky, Klein, Moss and Page, and gets their expert opinions on late-breaking clinical trial data released at ESC 09 and how it will affect patient care.
The ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation were published in 2006. Since this publication, new data and treatment options have been developed. Join Drs. Prystowsky, Hohnloser, and Kowey, as they discuss these new data and strategies for implementation in clinical practice.
Atrial fibrillation affects nearly 7 million people in the United States and Europe. Please join Drs. Breithardt, Connolly, Crijns, Kirchhof, and Naccarelli for a discussion on strategies to improve outcomes in patients with AF.
Hypertension plays a key role in the pathogenesis of atrial fibrillation. Join our expert panel, Drs. Agabiti-Rosei, Allessie, Crijns, Israel, and Weber for a discussion of the current data and treatment options for optimal management and improving outcomes in hypertensive patients with AF.
Join Prof. Santini and Drs. Gimbel and Sommer as they discuss the outstanding challenges surrounding the safety of MRI in patients with implantable cardiac pacing devices and highlight emerging strategies and technological advances that may help increase access to diagnostic care for patients.
Do we have enough data to suggest that MRI in pacemaker patients is safe? Join Dr. Roger Luechinger as he discusses safety concerns and novel approaches to overcome some of the existing limitations associated with imaging this population of patients.
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.
The association between stroke and AF has been well established. Join Drs. Diener, Norrving, Torp-Pedersen, and Sacco, as they present new data from the 2009 EuroStroke meeting in Stockholm, Sweden, for preventing stroke and improving outcomes in patients with AF.
AF is the leading cause of arrhythmia-related hospitalizations and affects nearly 7 million people in the United States and Europe. Please join Drs. Dorian, Curtis, and Hohnloser for a discussion on strategies to reduce hospitalization rates for patients with AF.
AF is the most common sustained arrhythmia and significantly increases an individual's risk for heart failure. Join our expert panel: Drs. Naccarelli, Cannon, and Connolly for an in-depth discussion of new data and management strategies for improving outcomes in patients with AF.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.
Join two of the world's leading experts in implantable devices, Dr. Bruce L. Wilkoff and Dr. George H. Crossley, as they discuss key issues surrounding the pros and cons of lead extraction.
Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF
How can we improve the survival, functional status and quality of life and decrease hospital readmissions for the growing number of patients with heart failure? Join our panel of experts, Drs. Cannom, Francis, Fonarow, Greenberg, and Klein as they discuss the optimal use of pharmacologic and device-based treatment options.
The world's first MR-conditional pacemaker system designed for safe use in MRI represents a major milestone in the evolution of ICDs. Dr. Bruce Wilkoff from the Cleveland Clinic speaks on the significance of having this new technology available to patients.
Join Drs. Prystowsky, Lau, and Oseroff as they provide an international perspective on the prevention of sudden cardiac arrest in the Pacific Rim and South America.
Dr. Ileana Piña discusses the design and outcomes of the MADIT-CRT trial with Drs. Moss and Estes, and how these new data may benefit patients with heart failure.
Does early intervention with CRT-D slow the progression of heart failure? Watch as Dr. David Cannom interviews Drs. Camm, Hlatky, Klein, Moss and Page, and gets their expert opinions on late-breaking clinical trial data released at ESC 09 and how it will affect patient care.
Rate control, rhythm control, new drugs and devices for anticoagulation -- the armamentarium of treatment options is expanding rapidly. Drs. Yancy, Cannon, and Boehmer discuss the latest treatment modalities for patients with AF.
There is an increasing epidemic; the threat is real. With prevalence up and recent therapeutic advances few, atrial fibrillation and the accompanying risk for stroke need to be uppermost in the minds of physicians caring for patients with cardiovascular risk factors. Join Dr. Jerry Naccarelli as he leads a panel of experts consisting of Drs. Osseroff, Capucci and Lau, in a discussion of this global problem.
Read Dr. Jonathan Piccini's review of prevention of stroke in AF and how the newly released results of clinical trials of novel antithrombotic agents will reduce the risk for stroke. Then listen to our international panel of experts, Drs. Camm, Granger, Prystowsky, and Yusuf, as they give their take on new data released at ESC 2009.
Evidence-based therapies, both pharmacologic and devices are well documented in published guidelines, but are they followed and implemented in practice? Is there a treatment gap? Is it all about education or the lack thereof? Drs. Yancy, Abraham, and Pfeffer confer on evidence from recent registries and trials.
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.
Atrial fibrillation is associated with a high risk for stroke, myocardial infarction, heart failure, and death. How does blockade of the renin-angiotensin system affect patient outcomes? Join our international panel of experts, Drs Camm, Connolly, Crijns, and Granger, as they discuss the ESC 09 hotline results of the ACTIVE-I trial.
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.